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  This disposition is not an opinion of the full Court and, pursuant to I.O.P. 5.7, 
does not constitute binding precedent. 
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SHWARTZ, Circuit Judge. 
  
Plaintiff Fresenius Kabi USA, LLC, a drug manufacturer, sued its competitors Par 
Sterile Products, LLC and Par Pharmaceutical Companies, Inc. (collectively “Par”), 
alleging that Par violated federal and state antitrust law.  The District Court granted Par’s 
motion for summary judgment.  Because the District Court declined to engage in the 
analysis required by In re Wellbutrin XL Antitrust Litigation Indirect Purchaser Class, 
868 F.3d 132 (3d Cir. 2017), we will vacate and remand.  
I 
A 
The events at issue arise from the development of vasopressin injection 
(“vasopressin”), a drug used to increase blood pressure in adults.  To obtain approval to 
introduce a new drug to the market, a manufacturer must file a New Drug Application 
(“NDA”) with the Food and Drug Administration (“FDA”).  See 21 U.S.C. § 355(a)-(b); 
21 C.F.R. § 314.50.  Manufacturers seeking to sell the generic version of a previously 
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approved drug must file an Abbreviated New Drug Application (“ANDA”).  See 21 
U.S.C. § 355(j); 21 C.F.R. § 314.92.  Both applications must contain descriptions of the 
drug’s chemical makeup, including its active pharmaceutical ingredient (“API”).  See 21 
C.F.R. §§ 314.50(d), 314.94(a)(5).  Though not technically required, one way for 
applicants to provide the necessary technical information about the API is to reference 
the API supplier’s drug master file (“DMF”).1  See 21 C.F.R. § 314.420(a).  This allows 
an API supplier to support the manufacturer’s application without revealing to the 
manufacturer confidential proprietary information.2   
Certain drugs, including vasopressin, were on the market before the FDA required 
manufacturers to follow the NDA and ANDA processes.  Accordingly, Fresenius Kabi, 
Par’s predecessor, and other manufacturers initially sold vasopressin without having filed 
those applications.  To encourage manufacturers to seek approval of their drugs, the FDA 
adopted a policy of removing unapproved products from the market once it approved an 
NDA for the same product.     
In September 2012, Par’s predecessor, JHP Pharmaceuticals, filed the first 
vasopressin NDA using API provided by BCN Peptides.  The NDA was approved in 
 
1 A DMF contains information concerning, among other things, a drug’s 
composition and the materials used to prepare it.  21 C.F.R. § 314.420(a).  The FDA does 
not substantively review the contents of a DMF when submitted, id., but performs a 
completeness review to ensure the DMF contains all relevant information.  The FDA will 
substantively review a DMF only in connection with NDAs, ANDAs, and similar 
submissions.  Id. 
2 An API supplier is not required to have a DMF to provide API.  In addition, 
DMF development and drug manufacturing can occur simultaneously.  A DMF need not 
be finalized until the drug application is filed. 
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April 2014 and Par introduced the product into the market as Vasostrict in November 
2014 and obtained patents on its formulations in 2016 and 2017.  Consistent with its 
policy, the FDA ordered others, including Fresenius Kabi, to stop selling their 
unapproved vasopressin products, leaving Vasostrict as the only vasopressin product on 
the market. 
Because Par already secured the NDA for vasopressin, Fresenius Kabi transitioned 
its efforts away from filing an NDA and toward filing an ANDA for a generic version of 
Vasostrict in the fall of 2014.  In the early development of its ANDA, Fresenius Kabi 
obtained API from BCN and received assurances that BCN would provide it access to its 
DMF.  In the summer of 2015, however, Fresenius Kabi learned that BCN and Par were 
negotiating an exclusive supply agreement.  In December 2015, BCN told Fresenius Kabi 
that it would consider an offer from Fresenius Kabi to enter an exclusive arrangement 
with it instead of Par, but Fresenius Kabi declined to provide a counteroffer.  By the fall 
of 2015, Fresenius Kabi began looking for alternative API suppliers.  Fresenius Kabi 
initially contacted Bachem and PolyPeptide—the only two API suppliers other than BCN 
with then-active DMFs—but both suppliers were also in exclusive arrangements with 
Par.3  Fresenius Kabi widened its search to non-DMF-holding suppliers, and at least two, 
Gyma/CS Bio and Flavine/Lummy, offered in December 2015 to supply vasopressin API 
samples as they became available.  Gyma/CS Bio had developed vasopressin API at a 
 
3 The parties dispute whether Par entered into exclusivity agreements with 
PolyPeptide and Bachem, but for the purposes of this appeal of a summary judgment 
ruling, we will view the fact in Fresenius Kabi’s favor.   
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pilot scale and offered to provide samples to Fresenius Kabi.  Flavine/Lummy indicated 
that it had the technology necessary to produce the API.  After narrowing the field to 
Hemmo, CS Bio, and AmbioPharm, Fresenius Kabi decided to work with Hemmo in 
March 2017.  Fresenius Kabi thereafter switched to Bachem upon learning that Bachem 
was no longer in an exclusive supply arrangement with Par.  In July 2019, Fresenius Kabi 
submitted its ANDA for a generic vasopressin injection.  At least five other drug 
manufacturers secured an API supplier quickly enough to also develop a generic 
vasopressin and file an ANDA.  Two manufacturers, Eagle and Sandoz, filed their 
ANDAs about a year or more before Fresenius Kabi, in April 2018 and August 2018, 
respectively.4   
B 
Fresenius Kabi sued Par for violating the Sherman Antitrust Act, 15 U.S.C. §§ 1, 
2, for violating New Jersey antitrust law, N.J. Stat. Ann. § 56:9-1 et seq., and for common 
law tortious interference, alleging that Par’s exclusivity agreements with BCN, Bachem, 
and PolyPeptide were anticompetitive.5  After discovery, the parties moved for summary 
judgment.  Although the District Court recognized that the “heart of Fresenius’ claims is 
 
4 Hemmo provided API for Eagle and Bachem provided API for Sandoz and 
permitted Sandoz to reference its DMF in the ANDA. 
5 Fresenius Kabi forfeited its tortious interference claim because it only mentioned 
the claim in the procedural history, in the “ruling presented for review” section, and in a 
point heading of its opening brief, and it provided no arguments in support of the claim.   
See FTC v. AbbVie Inc., 976 F.3d 327, 368 n.3 (3d Cir. 2020) (“[A]rguments raised in 
passing . . . but not squarely argued[] are forfeited on appeal.” (internal quotation marks 
omitted) (quoting John Wyeth & Bro. Ltd. v. CIGNA Int’l. Corp., 119 F.3d 1070, 1076 
n.6 (3d Cir. 1997))); United States v. Pelullo, 399 F.3d 197, 222 (3d Cir. 2005) (stating 
that failure to raise an argument in an opening brief constitutes waiver).   
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that Par . . . delayed generic Vasopressin manufacturers’ entrance into the market by 
entering into exclusive [supply] agreements,” Fresenius Kabi, USA, LLC v. Par Sterile 
Prods., LLC, No. 16-4544, 2020 WL 901967, at *3 (D.N.J. Feb. 25, 2020), it did not 
evaluate whether the exclusive arrangements were anticompetitive.  Rather, the Court 
focused on whether Par’s patents broke “the chain of causation” between the allegedly 
anticompetitive conduct and Fresenius Kabi’s purported injury because the patents 
“independently would have prevented market entry.”  Id. (internal quotation marks 
omitted) (quoting Wellbutrin, 868 F.3d at 165).  Fresenius Kabi argued that the patents 
would not have blocked entry because they are invalid and, even if valid, the product for 
which it originally planned to file an ANDA would not infringe them.  The Court 
declined to evaluate Fresenius Kabi’s patent validity and noninfringement claims because 
there was no actual patent litigation or filed ANDA on which a jury could consider these 
claims and thus the Court would be undertaking a purely hypothetical patent exercise.  Id. 
at *4-5, *5-7.  As a result, the Court concluded that Par’s patents broke the chain of 
causation and so Fresenius Kabi’s antitrust claims could not succeed.  Id. at *7. 
Fresenius Kabi appeals.   
II6 
 “To establish an actionable antitrust violation, [a plaintiff] must show both that 
[the defendant] engaged in anticompetitive conduct and that [the plaintiff] suffered 
 
6 The District Court had jurisdiction under 15 U.S.C. § 15(a) and 28 U.S.C. 
§§ 1331, 1367.  We have jurisdiction under 28 U.S.C. § 1291.  
“We employ a de novo standard of review to grants of summary judgment, 
applying the same standard as the District Court.”  Eisai, Inc. v. Sanofi Aventis U.S., 
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antitrust injury as a result.”  Eisai, Inc. v. Sanofi Aventis U.S., LLC, 821 F.3d 394, 402 
(3d Cir. 2016).7  The District Court focused on the element of antitrust causation and 
concluded that because Par’s patents would have blocked Fresenius Kabi’s entry into the 
market, Fresenius Kabi could not show that the exclusivity agreement Par had with BCN 
caused an antitrust injury.   
In Wellbutrin, 868 F.3d at 132, we considered how to handle an assertion that a 
patent would have blocked an antitrust plaintiff’s entry into the market, and the patent 
would therefore break the chain of causation between the defendant’s allegedly 
anticompetitive conduct and the plaintiff’s injury.  Because a patent would break the 
chain of causation, we discussed whether a district court, as part of an antitrust case, must 
consider challenges to the patents.  Id. at 166-67.  We recognized that when a product 
infringes a valid patent, that patent blocks the plaintiff’s entry into the market and 
 
LLC, 821 F.3d 394, 402 (3d Cir. 2016) (internal quotation marks omitted) (quoting 
Montone v. City of Jersey City, 709 F.3d 181, 189 (3d Cir. 2013)).  We “view the 
underlying facts and all reasonable inferences therefrom in the light most favorable to the 
party opposing the motion,” and we “shall grant summary judgment if the movant shows 
that there is no genuine dispute as to any material fact and the movant is entitled to 
judgment as a matter of law.”  Id. (italics and internal quotation marks omitted) (quoting 
Montone, 709 F.3d at 189; Fed. R. Civ. P. 56(a)).  However, “antitrust law limits the 
range of permissible inferences that can be drawn from ambiguous evidence.”  Race Tires 
Am., Inc. v. Hoosier Racing Tire Corp., 614 F.3d 57, 73 (3d Cir. 2010) (internal 
quotation marks omitted) (quoting Harrison Aire, Inc. v. Aerostar Int’l, Inc., 423 F.3d 
374, 380 (3d Cir. 2005)).  Accordingly, “the plaintiff in an antitrust case responding to a 
summary judgment motion must overcome a higher threshold, which is imposed in order 
to avoid deterring innocent conduct that reflects enhanced, rather than restrained, 
competition.”  Id. (internal quotation marks omitted) (quoting In re Flat Glass Antitrust 
Litig., 385 F.3d 350, 357 (3d Cir. 2004)). 
7 This test governs both federal and state law antitrust claims.  See Eisai, 821 F.3d 
at 402 & n.11. 
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precludes a claim that the defendant’s allegedly anticompetitive conduct caused the 
plaintiff’s injury.  Id. at 165.  Accordingly, we held that the district court “must consider 
the substance of” those patent claims, id. at 167, because where a valid patent 
independently blocks the plaintiff’s entry into the relevant market, the defendant’s 
allegedly anticompetitive conduct cannot be the cause of the plaintiff’s injury, id. at 167 
n.58.   
Here, the District Court declined to engage in this analysis because Fresenius Kabi 
had not filed an ANDA and there was no litigation challenging the patents.8  Fresenius 
Kabi, USA, 2020 WL 901967, at *6-7.  Wellbutrin, however, does not require that patent 
litigation be commenced or that an ANDA be filed for a court to determine whether the 
patent breaks the chain of causation.9  868 F.3d at 167.  Rather, an argument that a patent 
would have blocked an antitrust plaintiff’s market entry, and a response that the patent is 
either invalid, or unenforceable, or the product at issue does not infringe it, triggers a 
patent analysis under Wellbutrin.  The analysis of such a hypothetical infringement suit 
or patent challenge may in some cases be predicted based on binding legal precedents, 
 
8 The District Court rejected two expert reports for the same reasons.  For 
example, the Court rejected Dr. Ralph Tarantino’s report because he did not review a 
draft ANDA or other elements that would have been in the proposed ANDA.  Fresenius 
Kabi USA, 2020 WL 901967, at *5.  The Court also rejected Dr. John Thomas’s report 
because he opined on the likely success in a patent action that had never been filed and 
was purely hypothetical.  Id. at *6.  While there may be other grounds to reject their 
opinions, the absence of a filed ANDA or an actual lawsuit challenging the patents does 
not provide a basis under Wellbutrin to decline considering patent challenges in the 
context of this antitrust case.  See Wellbutrin, 868 F.3d at 167. 
9 While the absence of a filed ANDA alone does not absolve a district court from 
engaging in this analysis, ambiguities in what the proposed ANDA would have 
contained, or other deficiencies in the record, may. 
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including statutory and case law.10  Whether the record permits the District Court to 
engage in such an analysis of course will be for it to decide.11  
 Because Wellbutrin required the District Court to examine the record to determine 
whether a reasonable jury could find that Par’s patents would have blocked Fresenius 
Kabi’s market entry, we will remand.12   
 
10 This scenario stands in contrast to City of Pittsburgh v. West Penn. Power 
Company, where the resolution of the underlying dispute was subject to the prerogative 
of an independent state administrative agency with broad supervisory power.  147 F.3d 
256, 259–60, 267–68 (3d Cir. 1998).   
11 The Northern District of Georgia’s decision in In re AndroGel Antitrust Litig. 
(No. II), No. 1:09-CV-955, 2018 WL 2984873 (N.D. Ga. June 14, 2018), should not 
influence this analysis.  That case is irreconcilable with Wellbutrin.  See AndroGel, 2018 
WL 2984873, at *14 (stating that experts who testify as to the likely outcome of 
underlying patent litigation, “like the expert relied upon in Wellbutrin, are coming up 
with probabilities out of whole cloth” (footnote omitted)). 
12 On remand, the District Court may choose to consider whether the exclusivity 
agreement even constitutes anticompetitive conduct because if it does not, then no patent 
analysis is needed.  An exclusivity agreement is unlawful under the rule of reason “only 
if the probable effect of the arrangement is to substantially lessen competition, rather than 
merely disadvantage rivals.”  Eisai, 821 F.3d at 403 (internal quotation marks omitted) 
(quoting ZF Meritor, LLC v. Eaton Corp., 696 F.3d 254, 271 (3d Cir. 2012)).  To 
evaluate the legality of such agreements, courts consider “whether a plaintiff has shown 
substantial foreclosure of the market for the relevant product,” and “the likely or actual 
anticompetitive effects of the exclusive dealing arrangement, including whether there was 
reduced output, increased price, or reduced quality in goods or services.”  Id.  Whether 
the defendant qualifies as a monopolist will also bear on this analysis.  Id. at 404.  
Various facts shed light on the issue of substantial foreclosure.  For example, the 
record shows that exclusivity arrangements are “fairly normal with generics,” App. 1065, 
and, in fact, Fresenius Kabi has entered into such arrangements.  The record also shows 
that Fresenius Kabi was offered the chance to compete for an exclusive arrangement with 
BCN for its API via a competitive monetary offer but declined to pursue it.  Race Tires, 
614 F.3d at 79, 84 (holding, under the facts of that case, that “to offer more money” is not 
coercive).  The record also reveals that there were other API suppliers who were willing 
to provide API to Fresenius, although they either had not yet begun or were in the early 
stages of producing vasopressin API.  In addition, other manufactures worked with 
suppliers other than BCN, and those manufacturers eventually filed ANDAs.  The 




For the foregoing reasons, we will vacate the District Court’s order granting 
summary judgment for Par and remand for further proceedings. 
 
period, see Geneva Pharms. Tech. Corp. v. Barr Lab’ys, Inc., 386 F.3d 485, 489-91, 502, 
509 (2d Cir. 2004) (vacating grant of summary judgment for the defendant drug 
manufacturers because there were disputed facts concerning whether viable alternate 
sources of API were available “to generic [drug] manufacturers during the period at 
issue”), or whether Par “foreclose[d] so large a percentage of the available supply” as to 
present a threat to competition, not just disadvantage to a rival, ZF Meritor, LLC, 696 
F.3d at 271, 284 (quoting Race Tires, 614 F.3d at 76).  In conducting this analysis, the 
absence or presence of a DMF is not in itself dispositive.  A manufacturer need not 
partner with a supplier with an active DMF during its development of an ANDA, and 
sometimes a drug applicant may choose to not reference a DMF in its ANDA filing at all.    
Fresenius Kabi itself has worked with API suppliers without an active DMF when 
developing other drugs, and since 2008 has filed six NDAs or ANDAs that did not 
reference a DMF.  If the District Court chooses to consider whether Par engaged in 
anticompetitive conduct, it is for that Court to decide whether there are disputes of 
material fact concerning these points and others that may be relevant to determining 
whether Par’s arrangement with BCN “bar[red] a substantial number of rivals or severely 
restrict[ed] the market’s ambit.”  Eisai, 821 F.3d at 403 (quoting United States v. 
Dentsply Int’l, Inc., 399 F.3d 181, 191 (3d Cir. 2005)).   
 
 
